Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frank Bridoux

Showing results (111-120 of 165) with videos related to

Pageof 17
Sort By:
Clinical Kidney Journal|December 4, 2023
Adding 6-month parameters for the prediction of kidney prognosis in ANCA-associated glomerulonephritisCharlotte Boud'hors, Jérémie Riou, Nicolas Fage, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|December 13, 2024
Epidemiological and clinicopathological characteristics of vascular-limited renal AL amyloidosisNoémie Senot, Jean Baptiste Gibier, Marion Rabant, et al.
The Lancet. Haematology|December 22, 2015
Natural history and outcomes in localised immunoglobulin light-chain amyloidosis: a long-term observational studyShameem Mahmood, Frank Bridoux, Christopher P Venner, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|April 9, 2019
Heavy Chain Fibrillary Glomerulonephritis: A Case ReportSamih H Nasr, Christophe Sirac, Frank Bridoux, et al.
Kidney International|January 22, 2015
Diagnosis of monoclonal gammopathy of renal significanceFrank Bridoux, Nelson Leung, Colin A Hutchison, et al.
Blood|December 23, 2018
Randall-type monoclonal immunoglobulin deposition disease: novel insights from a nationwide cohort studyFlorent Joly, Camille Cohen, Vincent Javaugue, et al.
The New England Journal of Medicine|September 15, 2007
High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosisArnaud Jaccard, Philippe Moreau, Veronique Leblond, et al.
Haematologica|May 27, 2014
Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naïve patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III)Arnaud Jaccard, Raymond L Comenzo, Parameswaran Hari, et al.
Blood|January 11, 2017
Treatment of B-cell disorder improves renal outcome of patients with monoclonal gammopathy-associated C3 glomerulopathySophie Chauvet, Véronique Frémeaux-Bacchi, Florent Petitprez, et al.
Kidney International|October 25, 2016
Unravelling the immunopathological mechanisms of heavy chain deposition disease with implications for clinical managementFrank Bridoux, Vincent Javaugue, Sébastien Bender, et al.
Pageof 17

Showing results (111-120 of 165) with videos related to

Sort By:
Pageof 17
Clinical Kidney Journal|December 4, 2023
Adding 6-month parameters for the prediction of kidney prognosis in ANCA-associated glomerulonephritisCharlotte Boud'hors, Jérémie Riou, Nicolas Fage, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|December 13, 2024
Epidemiological and clinicopathological characteristics of vascular-limited renal AL amyloidosisNoémie Senot, Jean Baptiste Gibier, Marion Rabant, et al.
The Lancet. Haematology|December 22, 2015
Natural history and outcomes in localised immunoglobulin light-chain amyloidosis: a long-term observational studyShameem Mahmood, Frank Bridoux, Christopher P Venner, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|April 9, 2019
Heavy Chain Fibrillary Glomerulonephritis: A Case ReportSamih H Nasr, Christophe Sirac, Frank Bridoux, et al.
Kidney International|January 22, 2015
Diagnosis of monoclonal gammopathy of renal significanceFrank Bridoux, Nelson Leung, Colin A Hutchison, et al.
Blood|December 23, 2018
Randall-type monoclonal immunoglobulin deposition disease: novel insights from a nationwide cohort studyFlorent Joly, Camille Cohen, Vincent Javaugue, et al.
The New England Journal of Medicine|September 15, 2007
High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosisArnaud Jaccard, Philippe Moreau, Veronique Leblond, et al.
Haematologica|May 27, 2014
Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naïve patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III)Arnaud Jaccard, Raymond L Comenzo, Parameswaran Hari, et al.
Blood|January 11, 2017
Treatment of B-cell disorder improves renal outcome of patients with monoclonal gammopathy-associated C3 glomerulopathySophie Chauvet, Véronique Frémeaux-Bacchi, Florent Petitprez, et al.
Kidney International|October 25, 2016
Unravelling the immunopathological mechanisms of heavy chain deposition disease with implications for clinical managementFrank Bridoux, Vincent Javaugue, Sébastien Bender, et al.
Pageof 17